BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daval International Limited Release: Detailed Molecular Analysis of Aimspro® to be Presented at the 16th Conference in Genomics and Proteomics of Human Pathogens 27-28 June


6/27/2013 8:36:50 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eastbourne, UK – Daval International limited (“Daval International” or “Daval”), the UK based biotechnology company focused on the development of its leading product AIMSPRO®, announces that Prof. Syed Haq, Chief Scientific and Medical Officer of Daval International and Dr Deirdre McIntosh, also affiliated with the Company, will present a poster at The 16th Conference in Genomics and Proteomics of Human Pathogens, 27-28 June, at Public Health England, Colindale, London.

Prof. Haq will present data on the detailed molecular characterisation of AIMSPRO® (Hyperimmune Caprine Sera, HICS) that has been carried out in collaboration with Public Health England (PHE). The work has involved the use of a range of cutting-edge biochemical techniques including surface-enhanced laser desorption/ionization (SELDI) time-of-flight (TOF) mass spectrometry (a mass spectrometry method used for the analysis of sensitive samples such as protein mixtures) and 1D/2D gel electrophoresis with proteomic analysis. This has led to greater insights in to the mechanism of action of the active components contained within the biologic. High Performance Capillary Electrophoresis with SELDI-TOF mass spectrometry has confirmed AIMSPRO®’s batch-to-batch consistency and stability. The active component of the drug has been determined as a multi-protein peptide complex that uniquely traverses the blood brain barrier offering potentially greater versatility in targeting a range of neurodegenerative disease states.

AIMSPRO® is being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. It has also shown promise in being able to target various viral and bacterial pathogens either directly or indirectly through associated released endotoxins.

Details of the poster and timing are as follows:

Title: A Potential Anti-Viral Therapy. A First-in-Class Animal-Derived Serum Purified Extract for Human and Veterinary Use

Presented by: Prof. Syed Haq, CSO and CMO, Daval International Ltd.

Date: 27 June 2013

Presentation time: 5pm-7pm

The abstract will be available for download on Daval International’s website by 1 July, 2013, 07:00 am GMT, see www.davalinternational.com.

For further information please contact:

Daval International Ltd

James Shotton +1 303 588 5881 or +44 (0)7739 648401

Chief Executive Officer

NM Rothschild

Julian Hudson +44 (0)20 7280 5000

FTI Consulting

Julia Phillips / Simon Conway +44 (0)20 7831 3113

About AIMSPRO®

AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a proprietary, purified, multi-protein-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. It is believed that the drug has a unique mechanism of action that supports its broad potential application in neurodegenerative diseases. AIMSPRO® has been granted a Specials License by the UK's MHRA and is also available in Australia under Categories A and B of the TGA's Special Access Scheme.

About Daval International Limited

Daval International Limited is a UK based biotechnology company focused on the development of its leading product AIMSPRO® as a novel treatment for serious unmet medical needs through a combination of innovation, dedication, skilled science, entrepreneurship and partnership. From its inception in 2000, the management team of Daval have had a vision of making available effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neurodegenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES